Related Experiment Video

Updated: Oct 4, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase

Priscilla K Brastianos1, Albert E Kim2, Nancy Wang2

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu.

Nature Cancer
|February 5, 2022
PubMed

Insights

The cyclin-dependent kinase (CDK) pathway is a potential target for brain metastases (BM). Palbociclib showed efficacy in a trial for patients with progressive BM and CDK alterations, supporting molecular testing for targeted therapy selection.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Molecular Therapeutics

Background:

  • Brain metastases (BM) represent a significant challenge in cancer care.
  • The cyclin-dependent kinase (CDK) pathway is emerging as a potential therapeutic target for BM.
  • Targeted therapies with central nervous system (CNS) penetration are needed for effective treatment of BM.

Purpose of the Study:

  • To evaluate the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM.
  • To assess the role of CDK alterations in predicting response to palbociclib in BM.
  • To provide interim analysis data for a basket trial investigating targeted therapy for BM.

Main Methods:

  • Interim analysis of a basket trial design.
  • Inclusion of patients with progressive brain metastases and identified CDK alterations.
  • Evaluation of intracranial efficacy of palbociclib, a CDK inhibitor.

Main Results:

  • The study met its primary endpoint, demonstrating efficacy of palbociclib.
  • Palbociclib showed activity in patients with progressive BM and CDK alterations.
  • Interim analysis supports the therapeutic potential of targeting the CDK pathway in BM.

Conclusions:

  • Targeting the CDK pathway with palbociclib is a viable strategy for treating brain metastases.
  • Molecular testing of archival BM tissue can inform the selection of CNS-penetrant targeted therapies.
  • Further investigation and patient stratification based on molecular alterations are warranted.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K